KRAS and cancer: At the single variant level the QCI software is able to identify an individual variant as an actionable cancer mutation, and provides links to current clinical research insights, e.g. the KRAS G12D somatic variant it is established to confer resistance to the colorectal cancer drugs cetuximab and panitumumab, based on evidence curated from their FDA drug labels and clinical practice guidelines.